Jane Ellen Carland

Jane Ellen Carland

Auto-generated profile, based on publicly available information

Jane Ellen Carland

Department of Clinical Pharmacology and Toxicology, St Vincent’s Hospital, Sydney, Australia

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2018 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
TLTom N. Lea-Henry
Tom N. Lea-Henry
JCJane E. Carland
Jane E. Carland
Sophie StockerSophie Stocker
Sophie Stocker
JSJacob Sevastos
Jacob Sevastos
DRDarren M. Roberts
Darren M. Roberts
Kidney disease is an increasingly common comorbidity that alters the pharmacokinetics of many drugs. Prescribing to patients with kidney disease requires knowledge about the drug, the extent of the patient’s altered physiology, and pharmacokinetic principles that influence the design of dosing regimens. There are multiple physiologic effects of impaired kidney function, and the extent to which they occur in an individual at any given time can be difficult to define. Although some guidelines are available for dosing in kidney disease, they may be on the basis of limited data or not widely applicable, and therefore, an understanding of pharmacokinetic principles and how to apply them is important to the practicing clinician. Whether kidney disease is acute or chronic, drug clearance decreases, and the volume of distribution may remain the same or increase. Although in CKD, these changes progress relatively slowly, they are dynamic in AKI, and recovery is possible depending on the etiology and treatments. This, and the use of kidney replacement therapies further complicate attempts to quantify drug clearance at the time of prescribing and dosing in AKI. The required change in the dosing regimen can be estimated or even quantitated in certain instances through the application of pharmacokinetic principles to guide rational drug dosing. This offers an opportunity to provide personalized medical care and minimizes adverse drug events from either under- or overdosing. We discuss the principles of pharmacokinetics that are fundamental for the design of an appropriate dosing regimen in this review.

2 October 2020 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
AXAntonia Xu
Antonia Xu
MBMelissa Therese Baysari
Melissa Therese Baysari
SSSophie Lena Stocker
Sophie Lena Stocker
LLLiang Joo Leow
Liang Joo Leow
RDRichard Osborne Day
Richard Osborne Day
JCJane Ellen Carland
Jane Ellen Carland
Background: Informed consent is often cited as the “cornerstone” of research ethics. Its intent is that participants enter research voluntarily, with an understanding of what their participation entails. Despite agreement on the necessity to obtain informed consent in research, opinions vary on the threshold of disclosure necessary and the best method to obtain consent. We aimed to investigate Australian researchers’ views on, and their experiences with, obtaining informed consent. Methods: Semi-structured interviews were conducted with 23 researchers from NSW institutions, working in various fields of research. Interviews were analysed and coded to identify themes. Results: Researchers reported that consent involved information disclosure, understanding and a voluntary decision. They emphasised the variability of consent interactions, which were dependent on potential participants’ abilities and interests, study complexity and context. All researchers reported providing written information to potential participants, yet questioned the readability and utility of this information. The majority reported using signed consent forms to ‘operationalise’ consent and reported little awareness of, and lack of support in implementing more dynamic informed consent procedures, such as verbal informed consent, that was fit for the purposes of their studies. Views on Human Research Ethics Committees (HRECs) varied. Some reported inconsistent, arduous inputs on the information form and consent process. Others expressed reliance on HRECs for guidance, viewing them as institutional safeguards. Conclusions: This study highlights the importance of transparent relationships, both between researchers and participants, and between researchers and HRECs. Where the relationship with study participants was reported as more robust, researchers felt that they were better able to ensure participants made better, more informed decisions. Where the relationship with HRECs was reported as more robust, researchers were more likely to view them as institutional safeguards, rather than as bureaucratic hindrances. Conscientious and mindful researchers are paramount to ensuring the procedure accommodates individual requirements. This study advocates that when designing ethical informed consent practices, researchers should be integrated as autonomous players with a positive input on the process, rather than, in the worst case, predatory recruiters to be curtailed by information forms and oversight.

24 July 2018 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
DRDarren M. Roberts
Darren M. Roberts
JSJacob Sevastos
Jacob Sevastos
JCJane E. Carland
Jane E. Carland
Sophie StockerSophie Stocker
Sophie Stocker
TLTom N. Lea-Henry
Tom N. Lea-Henry
A change in pharmacokinetics can alter drug exposure and predispose the patient to either over- or underdosing, potentially resulting in adverse drug reactions or therapeutic failure. Kidney disease is characterized by multiple physiologic effects, which induce clinically significant changes in pharmacokinetics. These vary between individuals and may be quantitated in certain instances. An understanding of pharmacokinetic concepts is, therefore, important for a rational approach to the design of drug dosing regimens for the delivery of personalized medical care. Whether kidney disease is acute or chronic, drug clearance decreases and the volume of distribution may remain unchanged or increase. AKI is defined by dynamic changes in kidney function, which complicates attempts to accurately quantify drug clearance. In contrast, changes in drug clearance progress more slowly with CKD. In general, kidney replacement therapies increase drug clearance, but the extent to which this occurs depends on the modality used and its duration, the drug’s properties, and the timing of drug administration. However, the changes in drug handling associated with kidney disease are not isolated to reduced kidney clearance and an appreciation of the scale of potential derangements is important. In most instances, the first dose administered in patients with kidney disease is the same as in patients with normal kidney function. However, in some cases, a higher (loading) initial dose is given to rapidly achieve therapeutic concentrations, followed by a lower maintenance dose, as is well described when prescribing anti-infectives to patients with sepsis and AKI. This review provides an overview of how pharmacokinetic principles can be applied to patients with kidney disease to personalize dosage regimens. Patients with kidney disease are a vulnerable population and the increasing prevalence of kidney disease means that these considerations are important for all prescribers.

1 March 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
THTim G. Hales
Tim G. Hales
JDJames I. Dunlop
James I. Dunlop
TDTarek Z. Deeb
Tarek Z. Deeb
JCJane E. Carland
Jane E. Carland
SKStephen P. Kelley
Stephen P. Kelley
JPJohn A. Peters
John A. Peters
Homomeric 5-hydroxytryptamine type 3A receptors (5-HT3ARs) have a single channel conductance (γ) below the resolution of single channel recording (966 ± 75 fS, estimated by variance analysis). By contrast, heteromeric 5-HT3A/B and nicotinic acetylcholine receptors (nAChRs) have picosiemen range γ values. In this study, single channel recordings revealed that replacement of cytoplasmic membrane-associated (MA) helix arginine 432 (-4′), 436 (0′), and 440 (4′) residues by 5-HT3B (-4′Gln, 0′Asp, and 4′Ala) residues increases γ to 36.5 ± 1.0 pS. The 0′ residue makes the most substantial contribution to γ of the 5-HT3AR. Replacement of 0′Arg by aspartate, glutamate (α7 nAChR subunit MA 0′), or glutamine (β2 subunit MA 0′) increases γ to the resolvable range (>6 pS). By contrast, replacement of 0′Arg by phenylalanine (α4 subunit MA 0′) reduced γ to 416 ± 107 fS. In reciprocal experiments with α4β2 nAChRs (γ = 31.3 ± 0.8 pS), replacement of MA 0′ residues by arginine in α4β2(Q443R) and α4(F588R)β2 reduced γ slightly. By contrast, the γ of double mutant α4(F588R)β2(Q443R) was halved. The MA -4′ and 4′ residues also influenced γ of 5-HT3ARs. Replacement of nAChR α4 or β2 MA 4′ residues by arginine made current density negligible. By contrast, replacement of both -4′ residues by arginine produced functional nAChRs with substantially reduced γ (11.4 ± 0.5 pS). Homology models of the 5-HT3A and α4β2 nAChRs against Torpedo nAChR revealed MA -4′, 0′, and 4′ residues within five intracellular portals. This locus may be a common determinant of ion conduction throughout the Cys loop receptor family.

1 August 2014 in Trends in Pharmacological Sciences
Verified
Journal Article
Open access
Robert VandenbergRobert Vandenberg
Robert Vandenberg
RRRenae M. Ryan
Renae M. Ryan
JCJane E. Carland
Jane E. Carland
WIWendy Imlach
Wendy Imlach
MCMacdonald Christie
Macdonald Christie
Opioids, local anesthetics, anticonvulsant drugs, antidepressants, and non-steroidal anti-inflammatory drugs (NSAIDs) are used to provide pain relief but they do not provide adequate pain relief in a large proportion of chronic pain patients and are often associated with unacceptable side effects. Inhibitory glycinergic neurotransmission is impaired in chronic pain states, and this provides a novel target for drug development. Inhibitors of the glycine transporter 2 (GlyT2) enhance inhibitory neurotransmission and show particular promise for the treatment of neuropathic pain. N-arachidonyl-glycine (NAGly) is an endogenous lipid that inhibits glycine transport by GlyT2 and also shows potential as an analgesic, which may be further exploited in drug development. In this review we discuss the role of glycine neurotransmission in chronic pain and future prospects for the use of glycine transport inhibitors in the treatment of pain.

11 August 2020 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
RKRanita Kirubakaran
Ranita Kirubakaran
Sophie StockerSophie Stocker
Sophie Stocker
SHStefanie Hennig
Stefanie Hennig
RDRichard Day
Richard Day
JCJane E. Carland
Jane E. Carland